spacer
home > news > detailed info
INDUSTRY NEWS AND PRESS RELEASES

Biotechpharma to Expand Process Development and GMP Manufacturing Capacity to 5,000L

Biotechpharma

Biotechpharma UAB will expand its existing manufacturing facility by adding a new line of bioreactors

Biotechpharma UAB, a leading biopharmaceutical Contract Development and Manufacturing Organization (CDMO), today announced further expansion of its fermentation capacity to 5,000L along with an additional state of the art process development laboratory, investing more than €50 million in the expansion.

Dr. Vladas Bumelis, Chairman of the Board, stated, “The expansion comes amid growing global demand for flexible and responsive outsourcing partners that are able to support the full product lifecycle, from upstream and downstream process development and optimization to GMP manufacturing of drug substance and formulated drug product.” With the new capacity, Biotechpharma continues to advance its mission of becoming a single-source CDMO able to support its worldwide customers with a full range of development and manufacturing services to support clinical and commercial manufacturing.

“We are thrilled to announce this latest expansion of our infrastructure, as it will allow us to better support our customers’ biological development programs with quality, speed and flexibility of service,” said Giedrius Žunda, CEO of Biotechpharma.

The new plant in Europe, located at the company’s site in Vilnius, Lithuania, will contain a new line of bioreactors for microbial fermentation at 5,000L scale and the necessary equipment for downstream processing operations. Flexible facility design will also allow for increased mammalian cell culture production capacities in addition to the already existing two lines of 1000-L and 2000-L for mammalian cell production, both equipped with single use bioreactors. Completion of the plant, which should be operational in Q4 2020, will result in an increase in Biotechpharma’s volume capacity by nearly a factor of two.

“With this latest expansion and plans for continued growth, we are better positioned than ever to meet the growing global demand for these specialized capabilities – and to become a fully integrated biopharmaceutical CDMO.” Said Frank Ternes, CBO of Biotechpharma.

 
About Biotechpharma
Biotechpharma is a contract development and manufacturing organization (CDMO) supporting worldwide customers. Its highly experienced biochemistry, biology and bioprocess engineering staff can deliver projects at any stage, from cell line construction and process development to cGMP production of biopharmaceutical products. High-quality performance and on-time delivery are guaranteed by a team of highly qualified and experienced researchers, engineers, technologists and management professionals. Visit http://www.biotechpharma.lt/

For Further Information Contact:
Phillip Neill
Global Marketing Director
Biotechpharma UAB
+44 7860 785622 (London)
email bd@biotechpharma.lt
web www.biotechpharma.lt
email Mokslininku st. 4. LT-08412 Vilnius, Lithuania
 
Print this page
Send to a friend
   
spacer
News and Press Releases

MedPharm announce expansion of partnership with Palvella Therapeutics in developing a new treatment for the debilitating rare disease, pachyonychia congenita

MedPharm Ltd have announced the expansion of their partnership with Palvella Therapeutics, Inc., a Philadelphia-based biopharmaceutical company focused on developing and commercialising therapies for debilitating, rare genetic diseases. To date, MedPharm has employed its world-renowned specialist formulation expertise to support Palvella’s development of a novel, high-strength rapamycin topical formulation for application to the skin (PTX 022) as a disease-modifying treatment for pachyonychia congenita (PC). Most recently, MedPharm has made arrangements to manufacture the clinical (IMP) batches for use in Palvella’s upcoming Phase 2/3 clinical study.
More info >>


White Papers

7 Common Myths about QP Training Debunked: A Guide for Senior Managers

RSSL

The role of the Qualified Person (QP) in the pharmaceutical industry is mandated by law (Directive 2001/83/EC, Directive 2001/20/EC, UK SI 2012/1916, UK SI 2004/103). Every holder of a relevant Manufacturers Authorisation (human and veterinary) must have at least one QP; without one, no batch of medicinal product can be certified for release for sale.
More info >>

Industry Events

SCOPE Europe – Summit for Clinical Ops Executives Europe

17-18 September 2019, Barcelona, Spain

Building on the success of its long-running US-based counterpart, Summit for Clinical Trials Operations Executives Europe (SCOPE Europe) is a two-day event serving clinical innovation leaders, clin ops execs, functional heads, category managers, and those responsible for the planning and management of clinical trials in Europe and the Rest of the World. The event will feature opening and closing plenary keynote sessions, five conference tracks, interactive breakout discussion groups, and networking. It is an opportunity for leaders from large, mid-sized, and small pharma, specialty pharma, biotech, vendor companies, and academic research centers to come together to share best practices and discuss the new era of analytics-driven and patient-centric trials.
More info >>

 
©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement